Over the past several years, fentanyl has become a growing topic of discussion across healthcare, public safety, treatment programs, and workplace drug testing.
As awareness has increased, many organizations have begun evaluating whether fentanyl screening should be included as part of their drug testing programs.
Why the change?
One reason is that fentanyl is not always included in traditional drug testing panels. Employers and program administrators who want visibility into fentanyl exposure often need to select expanded panel configurations or testing devices that specifically include fentanyl screening.
Another factor is education. As organizations learn more about synthetic opioids and how testing panels are structured, they are taking a closer look at whether their existing testing programs align with their current objectives.
The decision to include fentanyl screening varies by industry, workplace environment, and program goals. Treatment providers, recovery programs, healthcare organizations, community service groups, and safety-sensitive employers may have different considerations when evaluating panel options.
The important takeaway is that adding fentanyl testing is not about following a trend. It is about understanding available testing options and determining whether additional screening aligns with an organization's specific needs.
As with any testing program decision, clarity starts with knowing what your panel includes and why.
Fact Friday takeaway:
More organizations are evaluating fentanyl testing as they review panel coverage, workplace risks, and program objectives.
Using a credible resource for drug screening supplies helps support consistency and reliability across your program.
